1007882-12-3

Usage

Uses

Used in Materials Science:
(S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y is used as a building block for the development of new materials with unique properties. Its boron and nitrogen atoms, along with the phenyl and imidazole rings, can contribute to the formation of novel materials with potential applications in various industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y can be employed as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its chiral nature and functional groups may allow for the development of enantiomerically pure drugs with improved efficacy and reduced side effects.
Used in Organic Synthesis:
(S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y can serve as a versatile reagent or catalyst in organic synthesis processes. Its unique structure and properties may enable the development of new synthetic routes and methodologies, leading to more efficient and selective reactions.
Used in Chemical Research:
(S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y can be utilized as a model compound in chemical research to study the effects of chirality, functional groups, and structural features on the compound's properties and reactivity. This research can provide valuable insights into the design and synthesis of new molecules with specific applications.

Upstream product

• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 147-85-3 L-proline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1007882-04-3 (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 1007881-98-2 y 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 

Downstream Products

• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 791-28-6 Triphenylphosphine oxide 
• 1007882-40-7 benzyl tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate) 
• 1007883-48-8 (S)-2-[5-(2-{4-[2-((S)-1-tert-butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-pyrimidin-5-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1181457-55-5 C₃₆H₃₉N₇O₃ 
• 1250937-01-9 C₄₂H₄₈N₆O₄ 
• 1369392-15-3 tert-butyl (S)-2-(5-(4-hydroxyphenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1241378-08-4 C₄₀H₄₆N₆O₄ 
• 1240428-03-8 C₃₄H₄₂N₆O₄ 
• 1255936-27-6 C₃₀H₄₈BN₃O₅Si 
• 1256383-42-2 (S)-2-{5-[4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)phenyl]imidazol-2-yl}pyrrolidine hydrochloride 
• 1240427-70-6 (S,S)-2-((4'-(2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-3H-imidazol-4-yl)biphenyl-4-ylmethyl)carbamoyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1256385-41-7 (S,S)-2-(6-(4-(2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-3H-imidazol-4-yl)phenyl)isoquinolin-1-ylcarbamoyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1256386-79-4 (2-methanesulfonyl-2-methyl-1-(2-(5-(4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)propyl)carbamic acid methyl ester 

Relevant academic research and scientific papers

Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir

A new approach to the synthesis of Emitasvir (DAG181), a small molecule hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor, is described. Enantioselective enzymatic desymmetrization with hydrolases in the synthetical approach can significantly avoid the loss of chiral raw materials in the resolution process. The synthesis route is further optimized and scaled-up to establish a new process that is applied to the preparation of kilogram scales of target active pharmaceutical ingredients (APIs). Compared with our initial process, the overall yield of target API was dramatically improved from 17 to 40%.

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES

Dicarbamate compounds as inhibitors of NS5A, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodmgs, and pharmaceutical compositions t

Daclatasvir hydrochloride impurity hydrochloride, preparation method and application thereof

The invention discloses daclatasvir hydrochloride impurity hydrochloride, a preparation method and application thereof, wherein the structure of the daclatasvir hydrochloride impurity is represented by a formula (I). The preparation method comprises the f

Monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and preparation method

The invention discloses a monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and a preparation method. The monoglycosyl-containing heterocyclic compound has a chemical structure represented by a formula I shown in the description. The monoglycosyl-containing heterocyclic compound disclosed by the invention can be used for effectively inhibiting protease of the hepatitis C viruses and treating infection of the hepatitis C viruses (HCV).

Hepatitis C virus inhibitors

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: [in-line-formulae]Q-G-A-L-B—Z—W??(I),[/in-line-formulae] which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF

The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: (structurally represented), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Hepatitis C virus inhibitors

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.